LUNIT INC
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Lunit Announces Collaboration with AstraZeneca to Develop AI-Powered Digital Pathology Risk Assessment Tools for NSCLC 2024-11-18 22:00
Lunit Partners with VIDI Group to Deliver AI-Powered Mammography to France's Largest Radiology Network 2024-11-13 22:00
Lunit Shows Promise of AI in Predicting Immunotherapy Response for Rare Cancer Patients at SITC 2024 2024-11-08 22:00
Lunit AI Predicts Breast Cancer Risk Up to 6 Years in Advance 2024-10-23 21:00
Lunit to Present AI-Analyzed Immune Phenotype Study as Immunotherapy Response Predictor for Advanced Gastric Cancer at ESMO Congress 2024 2024-09-10 21:00
Lunit Joins Roche's Digital Pathology Open Environment to Advance Cancer Biomarker Testing 2024-09-09 21:00
Immune Phenotyping Identified as Promising Predictive Biomarker by Lunit AI in Biliary Tract Cancer - New publication in CCR 2024-09-03 21:00
Lunit's AI for Tuberculosis Detection Tops in 12-Product Comparative Study 2024-08-06 21:00
Lunit's AI Solution Enhances Qatar's National Breast Cancer Screening Program 2024-07-22 21:00
Lunit to Showcase 7 Studies at ASCO 2024, including AI Innovations in HER2 Quantification, and Multimodal Predictive Models for Immunotherapy Response 2024-05-24 22:07
Lunit Completes Acquisition of Volpara: Pioneering Next-Level of AI-Driven Cancer Care 2024-05-22 21:00
Lunit Achieves Historic Milestone: 100 Peer-Reviewed Papers Published on Its AI Medical Imaging Suite 2024-05-20 21:00
Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals 2024-04-08 21:00
Lunit to Showcase 7 Studies at AACR 2024: Unveiling AI Innovations in HER2 Expression-Mutation Analysis and CNTN4 Biomarker Identification 2024-04-01 21:00
Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients 2024-03-26 21:00
Lunit Expands Presence in Europe: to Deliver AI-powered Cancer Screening Solution to France and Portugal 2024-03-18 21:00
Lunit SCOPE AI Enhances Pathologist Concordance and Accuracy in HER2, ER, and PR Assessment - New Study in Breast Cancer Research 2024-03-14 21:00
Update on Lunit's Acquisition of Volpara: New Zealand High Court Initial Approval Secured 2024-03-13 21:00
Lunit Presents Seven Study Results at ECR 2024: Showcasing AI's Robust Performance in Diverse Clinical Settings 2024-02-28 22:03
New Study Demonstrates Predictive Value of Lunit SCOPE IO to Predict Outcomes of Immune Checkpoint Inhibitor Therapy Across Diverse Tumors - published in the JITC 2024-02-16 22:03
1 2 3 4 5 6